Harry A. Peters

2.7k total citations
32 papers, 2.3k citations indexed

About

Harry A. Peters is a scholar working on Cancer Research, Molecular Biology and Oncology. According to data from OpenAlex, Harry A. Peters has authored 32 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Cancer Research, 14 papers in Molecular Biology and 9 papers in Oncology. Recurrent topics in Harry A. Peters's work include Protease and Inhibitor Mechanisms (15 papers), Cell Adhesion Molecules Research (7 papers) and Peptidase Inhibition and Analysis (4 papers). Harry A. Peters is often cited by papers focused on Protease and Inhibitor Mechanisms (15 papers), Cell Adhesion Molecules Research (7 papers) and Peptidase Inhibition and Analysis (4 papers). Harry A. Peters collaborates with scholars based in Netherlands, Germany and Denmark. Harry A. Peters's co-authors include John A. Foekens, Maxime P. Look, J.G.M. Klijn, W L van Putten, Marion E. Meijer‐van Gelder, Manfred Schmitt, Jan G.M. Klijn, F. Jänicke, Henk Portengen and J.G.M. Klijn and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Harry A. Peters

31 papers receiving 2.3k citations

Peers

Countries citing papers authored by Harry A. Peters

Since Specialization

Citations

This map shows the geographic impact of Harry A. Peters's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harry A. Peters with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harry A. Peters more than expected).

Fields of papers citing papers by Harry A. Peters

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harry A. Peters. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harry A. Peters. The network helps show where Harry A. Peters may publish in the future.

Co-authorship network of co-authors of Harry A. Peters

This figure shows the co-authorship network connecting the top 25 collaborators of Harry A. Peters. A scholar is included among the top collaborators of Harry A. Peters based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harry A. Peters. Harry A. Peters is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dendritic cell therapy in glioblastoma multiforme 2007 ·Journal of Clinical Oncology ·(unknown), T. Neßelhut, Raymond Chang, (unknown), (unknown), Ingo Wilke, (unknown), D. Lorenzen, (unknown), Harry A. Peters, Wolfgang Lüke	2
2	Implementation and Performance Study of a New NAT/Firewall Signaling Protocol 2006 ·(unknown), Harry A. Peters, Xiaoming Fu	3
3	Tumor Tissue Levels of Tissue Inhibitor of Metalloproteinase-1 as a Prognostic Marker in Primary Breast Cancer 2004 ·Clinical Cancer Research ·Anne‐Sofie Schrohl, Mads Holten-Andersen, Harry A. Peters, (unknown), Marion E. Meijer‐van Gelder, Jan G.M. Klijn, Nils Brünner, John A. Foekens	108
4	Clinical relevance of biologic factors in male breast cancer 2001 ·Breast Cancer Research and Treatment ·Marion E. Meijer‐van Gelder, Maxime P. Look, Joan Bolt‐de Vries, Harry A. Peters, Jan G.M. Klijn, John A. Foekens	43
5	High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. 2001 ·PubMed ·John A. Foekens, Harry A. Peters, Nicolaï Grebenchtchikov, Maxime P. Look, Marion E. Meijer‐van Gelder, Anneke Geurts‐Moespot, Theodorus van der Kwast, Fred C.G.J. Sweep, J.G.M. Klijn	255
6	The urokinase-type plasminogen activator system in resected non-small-cell lung cancer 2000 ·Annals of Oncology ·Martin Salden, T. A. W. Splinter, Harry A. Peters, (unknown), Mieke Timmermans, (unknown), John A. Foekens	46
7	The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. 2000 ·PubMed ·John A. Foekens, Harry A. Peters, Maxime P. Look, Henk Portengen, Manfred Schmitt, Michael D. Kramer, Nils Brünner, F. Jänicke, Marion E. Meijer‐van Gelder, S.C. Henzen‐Logmans, Wim L.J. van Putten, J.G.M. Klijn	351
8	Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer 1999 ·British Journal of Cancer ·J Witte, Fred C.G.J. Sweep, J.G.M. Klijn, (unknown), Harry A. Peters, Maxime P. Look, (unknown), J.J.T.M. Heuvel, Joan Bolt‐de Vries, T J Benraad, John A. Foekens	37
9	Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients 1999 ·British Journal of Cancer ·J Witte, Fred C.G.J. Sweep, J.G.M. Klijn, (unknown), Harry A. Peters, Maxime P. Look, (unknown), J.J.T.M. Heuvel, Wim L.J. van Putten, Th. J. Benraad, John A. Foekens	38
10	Breast-Conserving Therapy: Proteases as Risk Factors in Relation to Survival After Local Relapse 1999 ·Journal of Clinical Oncology ·Marion E. Meijer‐van Gelder, Maxime P. Look, Joan Bolt‐de Vries, Harry A. Peters, Jan G.M. Klijn, John A. Foekens	16
11	Uptake and distribution of doxorubicin in hormone-manipulated human breast cancer cells in vitro 1998 ·Breast Cancer Research and Treatment ·M. Bontenbal, Anieta M. Sieuwerts, Harry A. Peters, Wim L.J. van Putten, (unknown), Jan G.M. Klijn	5
12	Urokinase-type-plasminogen-activator(UPA) production by human breast (myo)fibroblastsin vitro: Influence of transforming growth factor-β1 (TGFβ1) compared with factor(s) released by human epithelial-carcinoma cells 1998 ·International Journal of Cancer ·Anieta M. Sieuwerts, Jan G.M. Klijn, Sonja C. Henzen‐Logmans, (unknown), Kees E. P. van Roozendaal, Harry A. Peters, Buddy Setyono-Han, John A. Foekens	30
13	Prognostic significance of cathepsins B and L in primary human breast cancer. 1998 ·Journal of Clinical Oncology ·John A. Foekens, Janko Kos, Harry A. Peters, Marta Krašovec, Maxime P. Look, Nina Cimerman, Marion E. Meijer‐van Gelder, S.C. Henzen‐Logmans, W L van Putten, J.G.M. Klijn	128
14	The MTT Tetrazolium Salt Assay Scrutinized: How to Use this Assay Reliably to Measure Metabolie Activity of Cell Cultures in vitro for the Assessment of Growth Characteristics, IC₅₀-Values and Cell Survival 1995 ·Clinical Chemistry and Laboratory Medicine (CCLM) ·Anieta M. Sieuwerts, Jan G.M. Klijn, Harry A. Peters, John A. Foekens	177
15	Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1: Predictors of Poor Response to Tamoxifen Therapy in Recurrent Breast Cancer 1995 ·JNCI Journal of the National Cancer Institute ·John A. Foekens, Maxime P. Look, Harry A. Peters, Wim L.J. van Putten, Henk Portengen, J.G.M. Klijn	138
16	Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. 1994 ·Journal of Clinical Oncology ·John A. Foekens, Manfred Schmitt, W L van Putten, Harry A. Peters, Michael D. Kramer, F. Jänicke, J.G.M. Klijn	185
17	Suramin: Pharmacokinetic monitoring, haematological and antitumor effects on rats bearing transplantable pancreatic tumors 1990 ·European Journal of Cancer and Clinical Oncology ·Buddy Setyono-Han, G.H. Bakker, Harry A. Peters, Anieta M. Sieuwerts, A.M.M. Eggermont, J.A. Foekens, J.G.M. Klijn	1
18	Growth factor-receptor pathway interfering treatment by somatostatin analogs and suramin: Preclinical and clinical studies 1990 ·The Journal of Steroid Biochemistry and Molecular Biology ·J.G.M. Klijn, Buddy Setyono-Han, G.H. Bakker, M.E.L. van der Burg, M. Bontenbal, Harry A. Peters, (unknown), P.M.J.J. Berns, John A. Foekens	21
19	Manipulation of cell cycle kinetics; influence on uptake, cellular distribution and cytotoxicity of doxorubicin 1990 ·European Journal of Cancer and Clinical Oncology ·M. Bontenbal, Anieta M. Sieuwerts, Harry A. Peters, Pieter Sonneveld, J.A. Foekens, J.G.M. Klijn	2
20	[Parenteral-peroral combined treatement of Crohn's disease and ulcerative colitis]. 1976 ·PubMed ·Harry A. Peters	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact